Spots Global Cancer Trial Database for advanced or metastatic breast cancer
Every month we try and update this database with for advanced or metastatic breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) | NCT04742153 | Advanced or Met... | MRG002 | 18 Years - | Shanghai Miracogen Inc. | |
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer | NCT05519059 | Advanced or Met... | Pelareorep | 18 Years - 70 Years | Adlai Nortye Biopharma Co., Ltd. | |
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer | NCT01199367 | Breast Cancer | KW-2450 in comb... | 18 Years - | Kyowa Kirin Co., Ltd. | |
Extended Treatment in Metastatic Breast Cancer With Eribulin | NCT02769364 | Breast Cancer | 18 Years - | Eisai Inc. | ||
A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer | NCT00748553 | Advanced or Met... Advanced or Met... | Azacitidine (Vi... Nab-paclitaxel ... | 18 Years - | University of Utah | |
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer | NCT05519059 | Advanced or Met... | Pelareorep | 18 Years - 70 Years | Adlai Nortye Biopharma Co., Ltd. | |
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer | NCT05519059 | Advanced or Met... | Pelareorep | 18 Years - 70 Years | Adlai Nortye Biopharma Co., Ltd. | |
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer | NCT01676753 | Advanced or Met... Triple Negative... | Dinaciclib Pembrolizumab | 18 Years - 85 Years | University of California, San Francisco | |
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors | NCT00511576 | Breast Cancer Lung Cancer Pulmonary Cance... Non-Small-Cell ... Prostate Cancer Prostatic Cance... Gastric Cancer Stomach Cancer | MGCD0103 & Doce... | 18 Years - | Mirati Therapeutics Inc. | |
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer | NCT05932667 | Advanced or Met... | Milademetan Patient Reporte... | 18 Years - | Institut Curie | |
Extended Treatment in Metastatic Breast Cancer With Eribulin | NCT02769364 | Breast Cancer | 18 Years - | Eisai Inc. | ||
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer | NCT01199367 | Breast Cancer | KW-2450 in comb... | 18 Years - | Kyowa Kirin Co., Ltd. | |
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer | NCT05932667 | Advanced or Met... | Milademetan Patient Reporte... | 18 Years - | Institut Curie | |
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer | NCT01199367 | Breast Cancer | KW-2450 in comb... | 18 Years - | Kyowa Kirin Co., Ltd. | |
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer | NCT04494425 | Advanced or Met... | Trastuzumab der... Capecitabine Paclitaxel Nab-Paclitaxel | 18 Years - 105 Years | AstraZeneca | |
Implementing Patients´ Competence in Oral Breast Cancer Therapy | NCT04030728 | Metastatic Brea... Advanced Breast... | 18 Years - | Onco Medical Consult GmbH | ||
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer | NCT04494425 | Advanced or Met... | Trastuzumab der... Capecitabine Paclitaxel Nab-Paclitaxel | 18 Years - 105 Years | AstraZeneca |